Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01033032
What this trial is testing

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SCRI Development Innovations, LLC 78
Testing effectiveness (Phase 2)Ended earlyNCT00852332
What this trial is testing

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
Centre Jean Perrin 42
Not applicableStudy completedNCT04987931
What this trial is testing

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 84
Testing effectiveness (Phase 2)Ended earlyNCT01185509
What this trial is testing

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07745257
What this trial is testing

Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

Who this might be right for
HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Sun Yat-sen University 40
Not applicableStudy completedNCT01293032
What this trial is testing

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Who this might be right for
Ductal Breast Carcinoma in SituLobular Breast Carcinoma in SituStage II Breast Cancer+4 more
Virginia Commonwealth University 59
Early research (Phase 1)Not Yet RecruitingNCT07163481
What this trial is testing

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

Who this might be right for
Stage IV (Metastatic) Breast Cancer
Hunan Cancer Hospital 12
Early research (Phase 1)Looking for participantsNCT07029399
What this trial is testing

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more
NiKang Therapeutics, Inc. 361
Early research (Phase 1)Study completedNCT04818632
What this trial is testing

AZD9833 China PK Study

Who this might be right for
ER+, HER2-, Metastatic Breast Cancer
AstraZeneca 28
Not applicableLooking for participantsNCT06711068
What this trial is testing

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 8,077
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT06001762
What this trial is testing

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Who this might be right for
Breast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma
Dana-Farber Cancer Institute 90
Not applicableActive Not RecruitingNCT07018427
What this trial is testing

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast NeoplasmsTriple Negative Breast CancerHR+, HER2-, Advanced Breast Cancer+1 more
Peking University Cancer Hospital & Institute 70
Early research (Phase 1)Looking for participantsNCT05683418
What this trial is testing

Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast Cancer
Totus Medicines 241
Not applicableUnknownNCT05870813
What this trial is testing

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Breast Carcinoma
Institut fuer Frauengesundheit 3,000
Large-scale testing (Phase 3)Study completedNCT00938652
What this trial is testing

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 519
Early research (Phase 1)Looking for participantsNCT06488378
What this trial is testing

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)UnknownNCT02829008
What this trial is testing

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
Chinese Academy of Medical Sciences 120
Testing effectiveness (Phase 2)Study completedNCT01082068
What this trial is testing

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 72
Testing effectiveness (Phase 2)Ended earlyNCT01776008
What this trial is testing

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeRecurrent Breast Carcinoma+5 more
National Cancer Institute (NCI) 16
Next Page